OBJECTIVE: Paid plasma donation has contributed to HIV epidemics in many countries. Eleven million liters of plasma are fractionated annually in the U.S., mainly from paid donors. Deferral of high-risk donors such as injection drug users (IDUs) is required for paid donations. We studied circumstances surrounding paid plasma donation among IDUs in two Mexico-U.S. border cities. METHODS: In 2005, IDUs > or = 18 years old in Tijuana (N=222) and Cd. Juarez (N=206) who injected in the last month were recruited through respondent-driven sampling. Subjects underwent antibody testing for HIV and HCV and an interviewer-administered survey including questions on donating and selling whole blood and plasma. RESULTS: Of 428 IDUs, HIV and HCV prevalence were 3% and 96%, respectively; 75 (17.5%) reported ever having donated/sold their blood or plasma, of whom 28 (37%) had sold their plasma for an average of $16 USD. The majority of IDUs selling plasma were residents of Ciudad Juarez (82%); 93% had sold their plasma only in the U.S. The last time they sold their plasma, 65% of IDUs had been asked if they injected drugs. Although the median time since last selling plasma was 13 years ago, 3 had done so within the prior 2 years, one within the prior 6 months; of these 3 IDUs, 2 were from Cd. Juarez, one from Tijuana; all 3 had only sold their plasma in the U.S. CONCLUSIONS: Although selling plasma appears uncommon among IDUs in these two Mexican border cities, the majority sold plasma in the U.S. and only one-third were deferred as high-risk donors. Paying donors for plasma should be a matter of public inquiry to encourage strict compliance with regulations. Plasma clinics should defer donors not only on behavioral risks, but should specifically inspect for injection stigmata.
OBJECTIVE: Paid plasma donation has contributed to HIV epidemics in many countries. Eleven million liters of plasma are fractionated annually in the U.S., mainly from paid donors. Deferral of high-risk donors such as injection drug users (IDUs) is required for paid donations. We studied circumstances surrounding paid plasma donation among IDUs in two Mexico-U.S. border cities. METHODS: In 2005, IDUs > or = 18 years old in Tijuana (N=222) and Cd. Juarez (N=206) who injected in the last month were recruited through respondent-driven sampling. Subjects underwent antibody testing for HIV and HCV and an interviewer-administered survey including questions on donating and selling whole blood and plasma. RESULTS: Of 428 IDUs, HIV and HCV prevalence were 3% and 96%, respectively; 75 (17.5%) reported ever having donated/sold their blood or plasma, of whom 28 (37%) had sold their plasma for an average of $16 USD. The majority of IDUs selling plasma were residents of Ciudad Juarez (82%); 93% had sold their plasma only in the U.S. The last time they sold their plasma, 65% of IDUs had been asked if they injected drugs. Although the median time since last selling plasma was 13 years ago, 3 had done so within the prior 2 years, one within the prior 6 months; of these 3 IDUs, 2 were from Cd. Juarez, one from Tijuana; all 3 had only sold their plasma in the U.S. CONCLUSIONS: Although selling plasma appears uncommon among IDUs in these two Mexican border cities, the majority sold plasma in the U.S. and only one-third were deferred as high-risk donors. Paying donors for plasma should be a matter of public inquiry to encourage strict compliance with regulations. Plasma clinics should defer donors not only on behavioral risks, but should specifically inspect for injection stigmata.
Authors: Johannes Blümel; Ivo Schmidt; Wolfgang Effenberger; Holger Seitz; Hannelore Willkommen; Hans Herrmann Brackmann; Johannes Löwer; Anna Maria Eis-Hübinger Journal: Transfusion Date: 2002-11 Impact factor: 3.157
Authors: M Melbye; K S Froebel; R Madhok; R J Biggar; P S Sarin; S Stenbjerg; G D Lowe; C D Forbes; J J Goedert; R C Gallo Journal: Lancet Date: 1984-12-22 Impact factor: 79.321
Authors: Hui Li; Katharine J Bar; Shuyi Wang; Julie M Decker; Yalu Chen; Chuanxi Sun; Jesus F Salazar-Gonzalez; Maria G Salazar; Gerald H Learn; Charity J Morgan; Joseph E Schumacher; Peter Hraber; Elena E Giorgi; Tanmoy Bhattacharya; Bette T Korber; Alan S Perelson; Joseph J Eron; Myron S Cohen; Charles B Hicks; Barton F Haynes; Martin Markowitz; Brandon F Keele; Beatrice H Hahn; George M Shaw Journal: PLoS Pathog Date: 2010-05-13 Impact factor: 6.823
Authors: Hui Li; Mark B Stoddard; Shuyi Wang; Lily M Blair; Elena E Giorgi; Erica H Parrish; Gerald H Learn; Peter Hraber; Paul A Goepfert; Michael S Saag; Thomas N Denny; Barton F Haynes; Beatrice H Hahn; Ruy M Ribeiro; Alan S Perelson; Bette T Korber; Tanmoy Bhattacharya; George M Shaw Journal: PLoS Pathog Date: 2012-08-23 Impact factor: 6.823